Bioliberty, an Edinburgh- and Boston-based rehabilitation technology startup, has raised a €2.95 million ($3.3 million) Series A extension, bringing its total funding to €12.07 million ($13.5 million).
The Series A extension adds four new institutional backers: TGH Ventures, the investment arm of Tampa General Hospital; Ballad Ventures; Belfast-based Whiterock; and 25m Health. The extension builds on the €9.12 million ($10.2 million) previously raised through pre-Series A and Series A rounds.
“This funding and our new strategic investors are crucial to our next phase: creating a more connected rehabilitation journey. We want to connect data across the patient journey, extend our technology into the home, and use AI to further augment therapy and assessment for physical and occupational therapists,” said Rowan Armstrong, co-founder and CEO, Bioliberty.
Bioliberty was founded in 2020 by Armstrong, Ross O’Hanlon, Conan Bradley, and Shéa Quinn, who hail from Northern Ireland. The company develops soft-robotic rehabilitation technology focused on upper-extremity recovery, primarily targeting patients who have suffered strokes or other mobility-limiting neurological conditions.
Its product suite is made up of three components: Lifehub, a portable control centre that powers the system and delivers interactive therapy sessions; Lifeglov, a soft robotic wearable glove powered by air that assists patients in opening and strengthening their hands; and Lifemind, a clinician-facing dashboard that centralises therapy data and uses AI to auto-generate clinical notes. Lifehub and Lifeglov are FDA-listed in the United States, where Bioliberty launched commercially in 2025.
Bioliberty says its technology was co-developed with leading inpatient rehabilitation facilities, enabling therapy sessions to begin in under five minutes and allowing patients to complete more repetitions per session.
“Bioliberty has been implemented by our therapists seamlessly. Patients are excited to see gains in their function and enjoy the interactivity of the tasks and games they can access,” said Ethan Clark, Therapy Manager, Methodist Rehabilitation Hospital.
For Bioliberty, the Series A extension will support three major priorities: extending its technology into the home environment, connecting rehabilitation data across different care settings, and building out additional AI capabilities to support clinical decision-making.
Bioliberty wants to be the technology provider that helps ensure that recovery does not stop when a patient leaves a rehabilitation facility. With a US base in Boston and partnerships with some of the most prominent rehabilitation providers in the United States, including a clinical study with Mount Sinai health system in 2024, it aims to become an end-to-end rehabilitation platform that works across hospital, post-acute, and home settings.
Source: EU-Startups
